Saurav Suman

| Aug 25, 2022 2:02 pm

Permalink

ACR50 response was similar in olokizumab as compared to adalimumab.
ACR70 responses were not checked.
Similar Side effects were noted in olokizumab as other IL6 receptor blockers such as transaminitis.

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.